Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 3,910 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostatic Cancer Clear all
Active, not recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

NCT03976843
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
New Orleans, Louisiana • Baltimore, Maryland • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice

NCT04763824
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
KanSurvive ECHO and Practice Facilitation
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Terminated No phase listed Observational

Adaptation of an eHealth (Web-application) Platform for Delivery of a Sedentary Behavior Intervention Among Prostate Cancer Patients

NCT03740035
View directory record Official record
Conditions
Sedentary Lifestyle
Interventions
eHealth for Sedentary Behavior
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Prostate Resection After Microwave Ablation (PRAMA)

NCT06128525
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Microwave Ablation, Multiparametric Magnetic Resonance Imaging, Questionnaire Administration, Radical Prostatectomy
Procedure · Device · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy

NCT00779168
View directory record Official record
Conditions
Prostate Cancer
Interventions
white button mushroom extract, flow cytometry, immunologic technique, laboratory biomarker analysis, gas chromatography-mass spectrometry, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

NCT01630590
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabozantinib, Androgen Ablation Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 1Phase 2 Interventional

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

NCT01543659
View directory record Official record
Conditions
Prostate Cancer
Interventions
89Zr-DFO-huJ591
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 3 Interventional

Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer

NCT00846976
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

NCT00510718
View directory record Official record
Conditions
Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
MDV3100
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
9
States / cities
Boston, Massachusetts • New York, New York • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 24, 2026, 4:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Clinical Trial Specific Question Prompt List

NCT00662324
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
focus groups
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Men's Prostate Awareness Church Training

NCT02131779
View directory record Official record
Conditions
Prostate Cancer
Interventions
Men's Workshops, Co-Educational Workshops
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
40 Years to 69 Years
Enrollment
536 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 24, 2026, 4:10 AM EDT
Enrolling by invitation No phase listed Observational

Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men

NCT06472817
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Terminated Not applicable Interventional

3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate

NCT00464724
View directory record Official record
Conditions
Prostate Cancer
Interventions
3T Magnetic Resonance Spectroscopic Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer

NCT01967862
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
computed tomography, bone scan, 3-Tesla magnetic resonance imaging, diffusion-weighted magnetic resonance imaging, fluorine F 18 sodium fluoride, positron emission tomography, laboratory biomarker analysis
Procedure · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 24, 2026, 4:10 AM EDT
Completed No phase listed Observational

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

NCT01138527
View directory record Official record
Conditions
Prostate Cancer
Interventions
MRI examination
Other
Lead sponsor
Radboud University Medical Center
Other
Eligibility
Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005627
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, docetaxel, estramustine phosphate sodium
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 24, 2026, 4:10 AM EDT
Not listed Not applicable Interventional

Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer

NCT02040610
View directory record Official record
Conditions
Prostate Cancer
Interventions
Hypofractionated Proton Therapy
Radiation
Lead sponsor
Provision Center for Proton Therapy
Other
Eligibility
18 Years and older · Male only
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Knoxville, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 2 Interventional

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

NCT00050596
View directory record Official record
Conditions
Prostate Cancer
Interventions
MDX-010 / MDX-010 + Docetaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Tucson, Arizona • Long Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 24, 2026, 4:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Strength, Aging, and Memory in Prostate Cancer

NCT04852224
View directory record Official record
Conditions
Prostate Neoplasm, Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 4:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT03431350
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
19
States / cities
Tucson, Arizona • Denver, Colorado • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Terminated Phase 1 Interventional

Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

NCT01155791
View directory record Official record
Conditions
Urologic Neoplasms, Prostate Cancer, Prostate Cancer Metastatic Disease
Interventions
Docetaxel, Biosyn, Prednisone
Drug
Lead sponsor
Sandy Srinivas
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 24, 2026, 4:10 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

NCT05828082
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib, Ultrasound Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Orange, California • Aventura, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Withdrawn Phase 1 Interventional

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

NCT01685489
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, PSK®, Docetaxel, Placebo
Drug
Lead sponsor
Bastyr University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 24, 2026, 4:10 AM EDT
Not listed Not applicable Interventional

ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation

NCT03504761
View directory record Official record
Conditions
Cellular Diagnosis, Prostate Cancer
Interventions
ClariCore Optical Biopsy System
Device
Lead sponsor
Precision Biopsy, Inc.
Industry
Eligibility
22 Years and older · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Denver, Colorado • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 24, 2026, 4:10 AM EDT